Skip to main content
Caplight Logo









Innervace

Innervace

Private
New York City, New YorkHealthcare & Life Scienceshttps://innervace.com

Last Round

Series A

Sep 8, 2022

Total Funding Raised

$41.1M

Company Overview

Innervace is a biotechnology company that develops implantable tissue-engineered brain pathways for the treatment of neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinecell therapytissue engineeringbiofabricationneural pathway reconstructionParkinson's disease treatmentneurodegenerative therapybrain circuitry repairimplantable neural scaffoldbiotech startupbrain repairneuro-regenerationbio-implant

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innervace Comparables

Compare Innervace with similar companies based on industry and business-model similarity.

Innervace comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kenai Therapeutics
84%
Oryon Cell Therapies
81%
BE Therapeutics
81%

Innervace Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 8, 2022

Key People

Founding team and executive leadership

Nader Halim

Chief Executive Officer

Executive Team

Innervace Investors

Notable investors and investment history

Innervace investors
InvestorRounds
Deerfield ManagementSeries A
IP GroupSeries A
WARF VenturesSeries A
Bio-Reference Laboratories, Inc.Series A
WARFSeries A
Anzu PartnersSeries A
Longview InnovationSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 8, 2022

    $40M round led by Deerfield Management

Innervace Filings

Explore SEC and related filing metadata, where available.

Innervace filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Innervace's valuation, stock price, and market status.

Is Innervace a public or private company?

Innervace is a private company.

What is the current stock price of Innervace?

Innervace is a private company with no public stock price. No recent secondary market data is available.

How much is Innervace worth (valuation)?

Valuation information for Innervace is not publicly available.

Can I buy Innervace stock?

Innervace shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Innervace's last funding round?

Innervace's most recent funding round was Series A on September 8, 2022.

Who are the main investors in Innervace?

Key investors in Innervace include Deerfield Management.

Will Innervace IPO soon?

No public IPO plans have been announced for Innervace.

How can I track Innervace secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Innervace's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range2
Year Founded2018
Last FundingSep 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?